DFTX

Following a bearish pivot confirmed by a red candle closing below the 9/20 EMAs as they crossed beneath the 50 SMA on rising volume, price has shifted into a medium-term downward repair. With EMAs now declining and no oversold exhaustion evident, the bias favors immediate selling into resistance at the failed EMA tests. Long-term uptrend remains intact above the 200 SMA, but a break and hold back above the EMAs would invalidate this bearish posture.

• ↑Late-stage DT120 trials targeting MDD/GAD with pivotal data due this year.
• ↑Wells Fargo raised ratings to strong-buy/overweight; PTs set at $68–73.
• ↓Q1 net loss widened to $77.1 M vs $23.3 M year-ago; R&D costs rose 77%.